Good day and welcome to the OptiNose third quarter, 2024 earnings call. At this time. All participants are in a listen-only mode after the speaker's presentation, there'll be a question and answer ...
Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 Company reports topline safety results from ENLIGHTEN 1 Phase 3 extension ...
Multiple organisms have been isolated from infected sinuses. However, it is important to note that "normal flora" has been cultured from healthy uninfected sinuses. "Normal flora" include ...
It indicates an expandable section or menu, or sometimes previous / next navigation options. Affiliate links for the products on this page are from partners that compensate us and terms apply to ...
Different RTIs were analysed separately, and this paper focuses on patients with acute sinusitis. Methods, design and patients: This was an open-label, prospective, uncontrolled, post-marketing ...